Company news
Nuvalent, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
May 11, 2022
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
April 7, 2022
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
April 6, 2022
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
March 30, 2022
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
March 7, 2022
Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
March 1, 2022
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
February 2, 2022
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
January 6, 2022
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
November 9, 2021
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
October 6, 2021
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
September 7, 2021
Nuvalent Announces Closing of Upsized Initial Public Offering
August 1, 2021